SAN DIEGO, Dec. 23 10, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new, synthetic, full-length genome of the SARS-CoV-2 virus. for the highly mutated and contagious Omicron variant (lineage B.1.1.529). Omicron has been identified as a variant of concern by the WHO and is spreading faster than any previous variant of SARS-CoV-2. The genome was constructed with the company’s BioXp™ 3250 system, a fully automated synthetic biology laboratory workstation for fast, accurate and reproducible DNA and mRNA writing.
“The DNA Codex team applauds the excellent work done by scientists in South Africa to rapidly identify and characterize the latest concerning variant of SARS-CoV-2, and we aim to honor their efforts by publishing this novel synthetic genome. to broaden access to research in laboratories. worldwide,” said Todd R. Nelson, PhD, CEO of Codex DNA. “This synthetic version of Omicron reflects our continued commitment to providing helpful tools and resources to scientists battling the COVID-19 pandemic.”
With the Omicron variant, Codex DNA offers a comprehensive catalog of 14 synthetic SARS-CoV-2 genomes as well as custom SARS-CoV-2 genomes that are used to support researchers in their search for solutions to fight specific variants . Additionally, Codex DNA offers custom DNA synthesis services to address the global pandemic. For customers interested in alternative variants of SARS-CoV-2, Codex DNA offers a wide range of synthetic controls that allow scientists to confidently verify and validate testing without the need for clinical virus samples.
All synthetic genomes produced by Codex DNA are manufactured in the United States and are available to researchers who pass a rigorous biosafety screening process to ensure responsible use. For more information on Codex DNA’s portfolio of tools to combat SARS-CoV-2, please visit https://codexdna.com/products/coronavirus/.
About Codex DNA
Codex DNA gives scientists the ability to create new synthetic biology-based solutions to many of humanity’s greatest challenges. As inventors of the industry standard Gibson assembly® and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA enables fast, accurate and reproducible DNA and mRNA writing for many downstream markets. The company’s award-winning BioXp™ system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. As a result, it offers virtually error-free large-scale DNA/RNA synthesis in days and hours instead of weeks or months. Scientists around the world are using this technology in their own labs to accelerate the design-build-test paradigm of new, high-value products for precision medicine, biologic drug discovery, vaccine and therapeutics development, genome and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on Codex DNA’s beliefs and assumptions and information currently available to it as of the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of Codex DNA to be materially different from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding Codex DNA’s ability to generate synthetic SARS-CoV-2 genomes and their utility in COVID-19 diagnosis and therapeutic discovery. These and other risks are described in more detail in documents filed by Codex DNA with the Securities and Exchange Commission (“SEC”) and in other documents that Codex DNA subsequently files with the SEC from time to time. other. Except to the extent required by law, Codex DNA assumes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Director